CRANBURY, N.J., Oct. 22, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that it has now achieved target enrollment and has 56 patients in its second Phase 3 study (Study 012) of migalastat HCl monotherapy for Fabry disease. Screening is now closed at participating sites, and final enrollment is anticipated by year-end 2012. Amicus, in collaboration with GlaxoSmithKline (GSK), is developing the investigational pharmacological chaperone Migalastat HCl for the treatment of Fabry disease.
